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Background. Invasive salmonellosis is a common community-acquired bacteremia in persons residing in sub-Saharan Africa. 
However, there is a paucity of data on severe typhoid fever and its associated acute and chronic host immune response and carriage. 
The Severe Typhoid Fever in Africa (SETA) program, a multicountry surveillance study, aimed to address these research gaps and 
contribute to the control and prevention of invasive salmonellosis.
Methods. A prospective healthcare facility–based surveillance with active screening of enteric fever and clinically suspected 
severe typhoid fever with complications was performed using a standardized protocol across the study sites in Burkina Faso, the 
Democratic Republic of Congo (DRC), Ethiopia, Ghana, Madagascar, and Nigeria. Defined inclusion criteria were used for screening 
of eligible patients for enrollment into the study. Enrolled patients with confirmed invasive salmonellosis by blood culture or patients 
with clinically suspected severe typhoid fever with perforation were eligible for clinical follow-up. Asymptomatic neighborhood con-
trols and immediate household contacts of each case were enrolled as a comparison group to assess the level of Salmonella-specific 
antibodies and shedding patterns. Healthcare utilization surveys were performed to permit adjustment of incidence estimations. 
Postmortem questionnaires were conducted in medically underserved areas to assess death attributed to invasive Salmonella infec-
tions in selected sites.
Results. Research data generated through SETA aimed to address scientific knowledge gaps concerning the severe typhoid fever 
and mortality, long-term host immune responses, and bacterial shedding and carriage associated with natural infection by invasive 
salmonellae.
Conclusions. SETA supports public health policy on typhoid immunization strategy in Africa.
Keywords. Severe typhoid fever, invasive Salmonellosis, host immunity and carriage, surveillance protocol, sub-Saharan Africa.
Invasive salmonellosis in humans is largely caused by fecal-
oral transmission of Salmonella enterica subspecies enterica 
serovars Typhi (S. Typhi) and Paratyphi A  (S. Paratyphi A), 
typically resulting in systemic typhoid fever (TF) and paraty-
phoid fever (PF), and nontyphoidal S. enterica (NTS) serovars 
causing self-limiting enterocolitis and bacteremia among chil-
dren and adults in sub-Saharan Africa. Globally, TF accounts 
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for 21.7 million cases and 217  000 deaths annually whereas 
invasive nontyphoidal Salmonella (iNTS) disease accounts 
for 3.4 million cases and >680 000 deaths [1, 2]. More recent 
systematic reviews of the burden of TF in low- and middle-
income countries (LMICs) suggest 20.6 million cases and 
223 000 deaths [3, 4], and adjusted for water-related risks and 
diagnostic factors, 11.9 million cases and 129 000 deaths [3]. 
A meta-regression analysis further estimated 17.8 million TF 
cases to occur each year in LMICs [5]. A recent multicountry 
TF surveillance study in Africa identified children <15 years 
and 3 years old as the prime risk groups for TF and iNTS di-
sease, respectively [6]. Antimicrobial-resistant (AMR) and 
multidrug-resistant (MDR) TF and iNTS disease are increas-
ingly reported from this region, highlighting the need for safe 
and effective vaccines and immunization strategies, particu-
larly in countries with high prevalence of AMR/MDR typhoid 
and iNTS disease [7–10].
Currently available typhoid vaccines include the parenteral 
unconjugated Vi polysaccharide (ViPS) and oral live attenuated 
Ty21a vaccines, both of which have been recommended by the 
World Health Organization (WHO) since 2008, and parenteral 
typhoid conjugate vaccine (TCV), which was prequalified by 
the WHO in December 2017 [11–13]. Infants <2 years old and 
children <6 years old for whom ViPS and Ty21a vaccines, re-
spectively, were not licensed, can now be immunized with TCV, 
which is licensed and recommended for infants aged 6 months 
or older [11, 14, 15]. Booster vaccinations are recommended 
for recipients of ViPS (every 2–3  years) and Ty21a (every 
3–7 years) in typhoid-endemic settings, but further studies are 
needed to inform the need for TCV boosting [11, 16]. No iNTS 
or paratyphoid vaccine is currently available. Because children 
and infants are at high risk from typhoid and iNTS disease in 
many sub-Saharan African countries, advancement of these 
vaccines is warranted in support of Sustainable Development 
Goal 3 [17], as well as a better understanding of disease burden 
and severity. Several publications suggest that AMR/MDR and 
clinical factors such as hypothermia and anemia are associated 
with TF mortality [18, 19].
However, there is a paucity of population-based data con-
cerning the incidence and severity of typhoid and iNTS disease 
among children and adults in sub-Saharan Africa. The Severe 
Typhoid Fever in Africa (SETA) program primarily aimed to 
understand the burden of severe TF and the associated case fa-
talities, clinical characteristics, and potential host risk factors 
that may be related to the disease severity. The SETA program 
also aimed to investigate the host immune response and bac-
terial shedding patterns associated with invasive salmonel-
losis. Public and private cost burden and productivity loss due 
to the treatment of respective diseases were further studied. 
Generated data will be essential in developing adequate immu-
nization strategies and typhoid and iNTS disease control and 
prevention policies. These SETA study results will have a direct 
impact, particularly in countries eligible for support from Gavi, 
the Vaccine Alliance, on potential uptake of TCV in the next 
10 years [20].
METHODS
SETA Study Objectives
The SETA program investigated (1) the burden and severity of 
invasive Salmonella infections (prospective surveillance with 
active screening at selected healthcare facilities); (2) host im-
munity and acute and chronic carriage associated with natural 
S. Typhi/S. Paratyphi A, B, and C (hereafter S. Paratyphi)/iNTS 
infections over a 1-year follow-up period (prospective case-
controlled and cohort study design method); (3) prevalences 
of S. Typhi/S. Paratyphi/NTS carriage in immediate household 
members of confirmed TF, PF, and iNTS disease cases (prospec-
tive active surveillance and cohort study); (4) public and pri-
vate expenditures for treatment and productivity loss (cost of 
illness) associated with TF/PF/iNTS disease (cohort) (5) effects 
of invasive salmonellosis on the quality of life of patients and 
long-term socioeconomic study (cohort); and (6) validation of a 
new reverse-transcription polymerase chain reaction (rt-PCR) 
assay for the diagnosis of invasive Salmonella infections (Table 
1). In addition to TF/PF/iNTS disease, other etiologies of bac-
teremia, Plasmodium infections, and viral hepatitides were also 
sought, where feasible, through testing at the study healthcare 
facilities and laboratories.
Study Sites
Building on the Typhoid Fever Surveillance in Africa Program 
(TSAP) network [6], the SETA program utilized and expanded 
on previously established fever surveillance infrastructure in 
sub-Saharan Africa. Six countries were selected exhibiting high 
disease endemicity (Burkina Faso, Ghana, Madagascar), fur-
ther need for in-country investigations on TF (Ethiopia), and 
value of extending to additional study sites to countries with 
large population numbers (Democratic Republic of Congo and 
Nigeria); study sites in these countries have been integrated into 
the SETA program to enable harmonized multicountry surveil-
lance and data comparability (Figure 1). Each SETA site has two 
distinct study areas (Table 2): a medically served area where 
surveillance and subsequent studies (case follow-up, enrollment 
and follow-up of neighborhood controls [NCs] and household 
contacts [HCs], healthcare utilization survey, and cost of illness 
and long-term socioeconomic studies) were performed, and a 
medically underserved area where the frequency of mortality 
due to suspected severe TF was assessed through postmortem 
questionnaires. The overall study period was between 2016 and 
2019, but varies per site (Table 2).
Surveillance sentinel sites were established including pri-
mary, secondary, and tertiary healthcare facilities (Table 
2). Selection of healthcare facilities was based on previous 
documentation of the occurrence of TF/PF/iNTS disease; 
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case reports or series of patients with severe TF; capacity to 
conduct blood culture and epidemiological research; acces-
sibility of local population to the healthcare facilities; and 
preference of healthcare facilities by the local population in 
the event of febrile illness. Each study site was characterized 
by having access to at least one tertiary hospital and at least 
one secondary or primary healthcare facility where patients 
were enrolled into the SETA program. Surveillance catch-
ment areas were predefined based on the geographic or ad-
ministrative coverage of healthcare services provided by 
respective healthcare facilities (hospital records or informa-
tion materials). Healthcare-seeking behavior data collected 
during TSAP and other existing national census and/or demo-
graphic data, generated through the Health and Demographic 
Surveillance System (HDSS) under the International Network 
for the Demographic Evaluation of Populations and Their 
Health (INDEPTH), were also considered [21, 22].
Prospective Sentinel-based Surveillance With Active Screening
Patients visiting SETA sentinel healthcare facilities were actively 
screened at selected entry points of each healthcare facility, in-
cluding triages where applicable, outpatient wards, inpatient 
medical and surgical wards, and emergency wards. Laboratories 
of the selected healthcare facilities/collaborating institutes 
were involved for laboratory-based detection of any invasive 
Salmonella from clinical samples such as blood and specimens 
from perforation cases, which may be collected outside of the 
routine SETA patient screening procedure. The generic SETA 
study forms are available in the Supplementary Data.
Inclusion Criteria and Specimen Collection
Patient screening for eligibility was based on the following in-
clusion criteria (Table 3): history of fever (≥3 consecutive days 
in the last seven days prior to visiting the healthcare facility), or 
current objectively assessed fever (≥38°C tympanic/rectal and/
or ≥37.5°C axillary), or clinically suspected TF or blood cul-
ture positive for invasive salmonellosis, or gastrointestinal per-
forations. Residency within the predefined catchment area was 
also an inclusion criterion, except for patients with clinically 
suspected severe TF complications such as gastrointestinal per-
forations who were eligible for enrollment regardless of catch-
ment residence (special cases; Table 4). Blood and stool samples 
were collected for culture from eligible patients at enrollment 
to investigate causative pathogens, antimicrobial resistance, and 
acute carriage (shedding), and urine samples were examined 
for antimicrobial pretreatment status (Table 5). Oropharyngeal 
swab samples were collected additionally for a supplemental in-
vestigation of group A Streptococcus carriage.
Severe Typhoid
Daily progress of clinical symptoms and treatment history 
were recorded for all enrolled patients with clinically sus-
pected severe TF (Table 4) until discharge, regardless of blood 
culture results. Patients with severe TF complications (Table 
Table 1. Objectives and Outcomes of the Severe Typhoid Fever in Africa Program
Objective Outcome
1. To estimate the burden and severity of invasive 
Salmonella infections 
a. Population-based adjusted incidence of invasive Salmonella infections 
b. Incidence of hospital- and community-based complications 
c. Mortality rate and long-term sequelae of Salmonella Typhi infections over 1 year of 
follow-up 
d. Prevalence of antimicrobial resistance among Salmonella isolates identified
2. To assess the immune response and carriage 
associated with natural TF, PF, and iNTS infection 
over a 1-year follow-up period
a. Assessment of the magnitude and duration of the immune response to TF, PF, and iNTS 
after natural infection 
b. Identification and validation of immunological markers associated with the develop-
ment of Salmonella Typhi, Salmonella Paratyphi, and iNTS carriage
3. To estimate the prevalence of S. Typhi, S. 
Paratyphi, and NTS carriers among immediate 
household members of positive Salmonella cases 
a. Prevalence of S. Typhi, S. Paratyphi, and NTS carriers among immediate household 
members of positive cases 
b. Immunological characterization of S. Typhi, S. Paratyphi, and NTS carriers 
c. Description of circulating S. Typhi, S. Paratyphi, and NTS isolates in the community and 
blood culture–confirmed cases
4. To estimate public and private expenditures for 
treatment and productivity loss associated with 
illness due to TF, PF, and iNTS infectionsa
a. Calculation of per-case direct and indirect cost of illness for TF, PF, and iNTS, categor-
ized by payer and stratified by age and type of service used
5. To estimate the effects of invasive salmonellosis 
on the quality of life of patients and the subse-
quent disease-related family and societal burdens 
over a 1-year follow-up perioda
a. Assessment of the quality of life of patients affected with invasive salmonellosis com-
pared to a control group over a 1-year follow-up period
6. To validate a new rt-PCR assay for the diagnosis 
of invasive Salmonella infections in selected SETA 
sitesb
a. Validation of rt-PCR assay for the diagnosis of invasive Salmonella infections
Abbreviations: iNTS, invasive nontyphoidal Salmonella; NTS, nontyphoidal Salmonella; PF, paratyphoid fever; rt-PCR, reverse-transcription polymerase chain reaction; SETA, Severe 
Typhoid Fever Surveillance in Africa program; TF, typhoid fever.
aNot applicable for Nigeria and the Democratic Republic of Congo.
bOnly for Burkina Faso and Ghana.
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6) requiring and/or undergoing surgery were closely moni-
tored by hospital physicians, who gauged the willingness of 
the patients to participate in this research on severe typhoid 
by providing sufficient information and accurate explanation 
concerning the study activities and expectations. Patient en-
rollment only occurred after written informed consent was 
obtained. In case of emergencies whereby patients with gas-
trointestinal perforations required an immediate surgical 
intervention, an existing hospital consent process/form for 
surgery was followed for patient treatment without delay. 
Such patients were approached after stabilization for informed 
consent for study participation. Where feasible and based on 
patient or/and guardian consent, treating physicians collected 
blood and/or surgical samples such as gastrointestinal tissue, 
gallbladder, bile, or peritoneal fluid for culture and/or PCR. 
Histopathology and cytology of surgical samples were per-
formed at the hospital, if feasible.
Assessment of death attributed to invasive Salmonella infec-
tion, particularly TF, was also analyzed through postmortem 
questionnaires (see Supplementary Data) performed in the 
medically underserved areas in selected study sites. While the 
International Statistical Classification of Diseases and Related 
Figure 1. Locations of the Severe Typhoid  Fever in Africa program sites. Population data sources: Burkina Faso: United Nations population division, Department of 
Economic and Social Affairs, 2014; Ouagadougou Health and Demographic Surveillance System routine data, 2015 (NiokoII/Polesgo nested in Ouagadougou); International 
Network for the Demographic Evaluation of Populations and Their Health. Democratic Republic of Congo: Kisantu Central Health Zone Office, 2017 (Nkandu/Kavwaya nested 
in Kisantu). Ethiopia: 2016 Ethiopia Health Management Information System, Ministry of Health. Ghana: Agogo Presbyterian Hospital official catchment area (Asante Akim 
North); 2010 Population and Housing Census (Asante Akim Central and Kumasi Metropolis). Madagascar: Ministry of Health, Repartition de la population par Fokotany, 2018 
(Imerintsiatosika); Madagascar Population Statistics from Institut National de la Statistique de Madagascar (National Institute of Statistics)/United Nations Population Fund, 
2015 (Antananarivo); commune census, 2019 (Belobaka). Nigeria: Annual Abstract of Statistics 2011, National Bureau of Statistics, Federal Republic of Nigeria. Abbreviation: 
INDEPTH, International Network for the Demographic Evaluation of Populations and Their Health.
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Health Problems, Tenth Revision (ICD-10) [23] and the verbal 
autopsy standards manual [24] recommended by the WHO 
were referenced, the SETA postmortem questionnaires adapted 
symptoms outlined in the case definition, which included pro-
longed history of fever before deterioration and death, at least 1 
abdominal-related symptom, deterioration consistent with the 
known TF complications such as acute abdomen or gastroin-
testinal bleeding or encephalopathic development with gradual 
deterioration to death, and history of treatment or hospitaliza-
tion. This questionnaire was also administered to participants 
enrolled in the medically served areas in case of any fatality 
occurring during the study period.
Host Immunity and Carriage Associated With Invasive Salmonellosis 
(Cases)
Enrolled patients with blood culture–confirmed TF/PF/iNTS 
(cases) became part of the study cohort for clinical follow-up 
and health economics surveys during the period of 1  year 
(Table 5). At each clinical follow-up visit, blood and stool sam-
ples were collected from all cases and additional oropharyngeal 
swab samples were obtained from iNTS cases. Immunological, 
biochemical, and parasitological assessments were conducted 
on the collected blood samples (immunoglobulin G [IgG]/im-
munoglobulin M [IgM] antibodies, complete blood count, ma-
laria, creatinine, bilirubin, alanine aminotransferase, aspartate 
aminotransferase, and additional peripheral blood mononuclear 
cell and T-cell stimulations where feasible in Ghana and Burkina 
Faso for a substudy on the cellular immune response associated 
with iNTS disease cases over the period of 1 year of follow-up). 
Stool culture was performed to detect bacterial shedding for 
assessment of acute and chronic carrier status up to the 1-year 
time point following the case confirmation [25, 26].
Neighborhood Controls
For investigations of host immune response and carriage 
status of cases in the context of the local population, asymp-
tomatic NCs matched to cases by age (±5  years), sex, and 
location of residency (1:4 case-control ratio) were enrolled 
(Table 3) following written informed consent. Neighborhood 
is defined based on the location of residency of TF/PF/iNTS 
cases within the surveillance catchment areas. Residency lo-
cations of cases noted for the study follow-up visits were ap-
plied to identify NCs, whereby neighbors residing within the 
same administrative units such as villages or communes were 
approached for age- and sex-matched criteria for screening 
and enrollment of NCs. Blood and stool samples were col-
lected at enrollment and at days 180 and 360. Oropharyngeal 
swab samples were collected additionally from iNTS disease 
case-matched controls. Immunological assessments were 
conducted on the collected blood samples, and stools were 
cultured for Salmonella.
Household Contacts
Upon identification of blood culture–positive TF/PF/iNTS 
cases, two immediate HCs were approached for study partici-
pation to investigate for carriage of S. Typhi, S. Paratyphi, and 
NTS. Household contacts are individuals residing in the same 
house as the case, sharing the common living condition and 
Table 3. Inclusion Criteria
Patient enrollment in tertiary healthcare facilities: 
1. Fever reported for ≥3 consecutive days within the last 7 days in patients living in the defined catchment area, OR 
2. Patients with clinically suspected TF living in the defined catchment area, OR 
3. Blood culture positive for Salmonella Typhi/Salmonella Paratyphi/iNTS (outside SETA) in patients living in the defined catchment area, OR 
4. Pathognomonic gastrointestinal perforations (ie, clinically diagnosed TF gastrointestinal perforation), even in the absence of laboratory confirmation, in pa-
tients living in and outside the defined catchment area (special cases), AND 
5. Informed consent form signed
Patient enrollment in primary and secondary healthcare facilities: 
1. Patients living in the defined catchment area presenting to healthcare facility with objective fever of ≥38°C tympanic/rectal AND/OR ≥37.5°C axillary, OR 
2. Fever reported for ≥3 consecutive days within the last 7 days in patients living in the defined catchment area, OR 
3. Patients with clinically suspected TF living in the defined catchment area, OR 
4. Blood culture positive for S. Typhi/S. Paratyphi/iNTS (outside SETA) in patients living in the defined catchment area, OR 
5. Pathognomonic gastrointestinal perforations (ie, clinically diagnosed TF gastrointestinal perforation), even in the absence of laboratory confirmation, in pa-
tients living in and outside the defined catchment area (special cases), AND 
6. Informed consent form signed
Neighborhood controls: 
1. Age (±5 years), sex, and residency (neighborhood) matched to S. Typhi/S. Paratyphi/iNTS disease and special cases, AND 
2. No subjective or objective fever at any point within 28 days prior to enrollment, AND 
3. No subjective or objective fever on the date of case enrollment (“focal time”), AND 
4. Informed consent form signed
Household contacts: 
1. Immediate household contacts of S. Typhi/S. Paratyphi/iNTS disease and special cases, AND priority should be given to: 
 (1) Individual(s) who prepares food for the case 
  (2) Individual(s) closest in age to the case 
  (3) Individual(s) who spends the most time with the case 
Alternative household contacts should be enrolled if individuals meeting the above priority do not wish to participate or are not identified. 
2. Informed consent form signed
Abbreviations: iNTS, invasive nontyphoidal Salmonella; SETA, Severe Typhoid in Africa program; TF, typhoid fever.
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environment. Priority for enrollment was given to individuals 
who prepare food for the case, who is the closest in age to the 
case, and who spends the most time with the case (Table 3). 
Frequency and duration of Salmonella carriage was estimated 
through confirmation of bacterial shedding in stool over the 
period of 1 year. Blood samples were also collected from imme-
diate HCs for the immunological characterization of Salmonella 
carriers (Table 4).
All samples collected and examined from study participants 
(cases/NCs/HCs) are described in Supplementary Table 1 (sum-
mary of sample collection for participants in SETA).
Healthcare Utilization Survey
A healthcare utilization survey [27] was conducted in the sur-
veillance catchment area to estimate the proportion of the pop-
ulation who seek healthcare at the SETA surveillance healthcare 
facilities in the event of any fever or symptoms consistent with 
severe enteric fever. This was used to derive age-specific adjust-
ment factors to adjust crude incidence rates of TF, PF, and iNTS 
disease in the catchment population [21]. In addition, socio-
economic and water, sanitation, and hygiene (WASH)–related 
data collected through the survey allow further observational 
analyses on the surveillance catchment population and settings.
Informed Consent and Ethical Considerations
All eligible participants (or their responsible parents/guardians) 
were approached for voluntary written informed consent. The 
informed consent process included an explanation by study 
staff about the study purpose, expectations from participants, 
duration of participation, risks and benefits for participation, 
confidentiality, right to decline or withdraw from the study, and 
contact information of study investigators. Participants were 
asked to sign a statement of consent if they agreed to join the 
study. If the participant was an infant or child, his or her parent/
guardian was asked to sign or thumbprint the statement of con-
sent. If the participant was an adolescent, both the participant 
and the parent/guardian were asked to sign or thumbprint the 
statement of consent. If the participant was illiterate, an inde-
pendent literate witness (where possible, this person should be 
selected by the participant and had no connection to the study 
team) was asked to sign or thumbprint the statement of consent. 
Study participants were allowed to withdraw from the study at 
any time without loss of clinical services or penalties of any 
kind. The International Vaccine Institute’s (IVI) Institutional 
Review Board and site-specific ethical review boards reviewed 
the study annually to ensure continued compliance with the 
ethical principles and guidelines based on the WHO (2009) 
[28], the Council for International Organizations of Medical 
Sciences (2016) [29] and the Declaration of Helsinki (World 
Medical Association Declaration of Helsinki, 2013).
Data Management
Data from each participant required complete and adequate 
source documentation (hospital or medical records, laboratory 
reports, test results) unless the data recorded directly on our 
study forms were considered the source data. The surveillance 
study forms included the informed consent and enrollment 
form for all participants, case report forms for patients, fol-
low-up forms for Salmonella-confirmed patients or/and special 
cases and their NCs and HCs, postmortem questionnaires, and 
laboratory forms (Supplementary Data). Electronic data collec-
tion was performed using the SETA Collect software (Android 
5.0.1; API 23) developed by the IVI for sites with stable internet 
access. In parallel, paper-based data collection was available at 
all sites. Data collected through SETA Collect were periodically 
exported to the IVI server via a web-based paperless data man-
agement system (PDMS). Paper-based data were entered into 
the computerized data management system (CDMS) using a 
Table 4. Case Definitions
Case Type Definition
Confirmed TF case Positive blood culture for Salmonella Typhi
Mild TF case Blood culture–confirmed TF without any complication of TF listed in Table 6
Severe TF casea Blood culture confirmed TF with any one complication(s) of TF listed in Table 6
Special caseb Pathognomonic gastrointestinal perforations (ie, clinically diagnosed TF gastrointestinal perforation), even in the absence 
of laboratory confirmation, in patients living in and outside the defined catchment area
Confirmed PF case Patients with a positive blood culture for Salmonella Paratyphi serovars
Confirmed iNTS disease case Patients with a positive blood culture for any nontyphoidal Salmonella serovar
Relapse Blood culture–confirmed case who becomes ill with a subsequent episode of TF/PF/iNTS disease within 90 days of the 
prime infection. (A relapse should be a discernably similar or identical infecting strain, for which further genomic ana-
lyses will be performed.)
Reinfection Blood culture–confirmed case who becomes ill with a subsequent episode of TF/PF/iNTS disease on or after a 90-day 
period after documentation of a previous blood culture–confirmed TF/PF/iNTS disease. (A reinfection should be a 
discernably different infecting strain, for which further genomic analyses will be performed.)
S. Typhi/S. Paratyphi/NTS carrier An individual shedding S. Typhi or S. Paratyphi or NTS in stool after symptom resolution.
Abbreviations: iNTS, invasive nontyphoidal Salmonella; NTS, nontyphoidal Salmonella; PF, paratyphoid fever; TF, typhoid fever.
aSevere typhoid: Refer to Table 6 for complications associated with TF.
bSpecial case: Refer to Table 3 for study inclusion criteria.
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dual entry process, which were transferred to the IVI monthly. 
This system automatically backed up data at systematic inter-
vals onto local hard disks and external media and provided an 
audit trail. In the event of data discrepancy or missing values, 
study staff referred to the original source documents or con-
tacted respective participants to clarify as needed. All tablets 
and PDMS/CDMS databases were password protected. All 
paper-based study forms were stored in cabinets with restricted 
access by authorized study staff. Both systems had algorithms 
for checking missing data points, range, and logical errors.
Data Analysis Methodology and Plan
SETA provides incidence rates and frequency proportions of TF. 
The incidence estimation is based on the formula used in TSAP 
[6, 30], using adjustments such as the proportion of healthcare-
seeking behavior in case of fever and severe febrile illnesses in 
the catchment population (denominator) and recruitment rate 
of study-eligible patients in the screened and enrolled patients 
(numerator) (Table 7). Equally, adjusted incidences, as well as 
frequency proportions of patients with severe TF (and deaths 
due to confirmed or/and suspected severe TF) out of the total 
number of TF cases are assessed. Final adjustment factors or 
multipliers to be applied in the adjusted incidence estimations 
are harmonized with the Severe Typhoid in Tanzania (STT) pro-
ject [31] and the Surveillance for Enteric Fever in Asia Project 
(SEAP) [30, 32, 33] sites to ensure data comparability. A  de-
scriptive analysis of frequency and prevalence of deaths due to 
suspected severe TF from the selected medically underserved 
areas will be presented. The clinical history of symptoms asso-
ciated with severe TF such as fever, abdominal pain, seizure, 
and other symptoms (Table 6) and the cause of death recorded, 
if known, are being made available. Due to the absence of aut-
opsies, any analysis on death attributable to suspected severe TF 
complications will remain descriptive and limited.
Analyses on severe TF will also include investigations on 
host risk factors that may be associated with the severity of 
Table 6. Possible Systemic Complications of Typhoid Fever
Complication Definition
Gastrointestinal bleedinga The presence of visible blood or melena in the stool with a positive fecal occult blood test
Gastrointestinal perforation Gastrointestinal perforation in the vicinity of the terminal ileum (or ileum/cecum/colon) typical of typhoid and seen at laparotomy 
(if available)
Encephalopathyb Patients with any of the following aspects of altered mental status: (1) Delirium: markedly confused thinking and speech; (2) 
Obtundation: patient who appears unconscious but can be stimulated to respond appropriately to questions and comments; 
(3) Stuporose: patient who does not respond appropriately to any stimuli but withdraws appropriately to noxious stimuli; (4) 
Comatose: patient who does not respond appropriately to noxious stimuli. These exclude patients with disorientation and 
poor short-term memory but not delirium; apathetic or lethargic without obtundation  
OR 
GCS score ≤12 and/or Blantyre score <5 without alternative diagnosis AND with CSF examination within normal limits (no WBC 
and a normal CSF glucose and protein)
Meningitis Symptoms suggestive of meningitis and an abnormal CSF examination with/without Salmonella Typhi or iNTS or Salmonella 
Paratyphi A isolated from CSF culture
Hemodynamic shocka Systolic blood pressure <90 mm Hg in patients aged ≥12 y or <80 mm Hg in patients aged <12 y with clinical evidence of tissue 
hypoperfusion (ie, abnormal state of consciousness; cold and clammy skin; constricted peripheral veins; oliguria [<20 mL 
urine/h] after rehydration)
Myocarditisa Abnormal cardiac rhythm or abnormal ECG as interpreted by physician; ultrasound evidence of a pericardial effusion; ventricular 
failure
Hepatitisa Visible jaundice and/or hepatomegaly with abnormal levels of serum SGOT (AST) (>400 IU/L) and/or SGPT (ALT) (>400 IU/L) or 
>5 times the ULN of liver enzyme tests
Cholecystitisa Right upper quadrant pain and tenderness without evidence of hepatitis; ultrasound evidence of enlarged gall bladder or gall 
bladder with thickened wall
Pneumoniaa Respiratory symptoms (eg, cough) with abnormal chest radiograph infiltrates
Pleural effusion Clinical (ie, shortness of breath, chest pain) and radiological evidence of a pleural effusion
Anemiac Moderate: 
Hb 7.0–9.9 g/dL in children aged 6–59 mo 
Hb 8.0–10.9 g/dL in older children and adults
Severe: 
Hb <7.0 g/dL in children aged 6–59 mo 
Hb <8.0 g/dL in older children and adults
Focal infection Abscess or collection at a specific site (eg, spleen, joint, bone) with Salmonella Typhi or Salmonella Paratyphi A isolates from 
drainage culture
Renal impairment Creatinine >2 mg/dL OR 175 μmol/L
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CSF, cerebrospinal fluid; ECG, electrocardiogram; GCS, Glasgow Coma Scale; Hb, hemoglobin; SGOT, Serum 
Glutamic Oxaloacetic Transaminase; SGPT, Serum Glutamic Pyruvic Transaminase; ULN, upper limit of normal; WBC, white blood cell.
aNdila C, Bauni E, Mochamah G, et al. Causes of death among persons of all ages within the Kilifi Health and Demographic Surveillance System, Kenya, determined from verbal autopsies 
interpreted using the InterVA-4 model. Glob Health Action 2014; 7:25593.
bLeung DT, Bogetz J, Itoh M, et al. Factors associated with encephalopathy in patients with Salmonella enterica serotype Typhi bacteremia presenting to a diarrheal hospital in Dhaka, 
Bangladesh. Am J Trop Med Hyg 2012; 86:698–702.
cWorld Health Organization; Chan M. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva, Switzerland: WHO, 2011:1–6.
S432 • cid 2019:69 (Suppl 6) • Park et al
disease (eg, age group, sex, and comorbidities) and site-specific 
characteristics. Various statistical methodologies will be used 
including the Spearman correlation coefficient and/or strati-
fied logistic regressions for univariate and multivariable ana-
lyses to measure the odds ratios. Data from the longitudinal 
cohort study of the TF/PF/iNTS patients and their respective 
NCs and HCs will be analyzed by comparing the level of anti-
bodies (IgG/IgM) of cases and their shedding of Salmonella 
species during an acute phase and up to a 1-year time point, 
with that of NCs and HCs (background antibody level and 
bacterial shedding in the respective households and commu-
nities). Salmonella strains detected in stools of cases, HCs, and 
NCs will be analyzed to investigate any patterns potentially 
related to transmissions in respective study sites, for which 
the population-based healthcare utilization survey data will be 
cross-compared for various environmental risk factors such as 
the household WASH conditions and domestic animals. All 
bacterial isolates yielded through SETA will be sequenced for 
further molecular epidemiological analyses such as the emer-
gence and spread of AMR/MDR strains as performed in TSAP 
[34]. Further analyses will be also performed including, but 
not limited to, the preuse of antimicrobials and/or antimal-
arials, AMR/MDR of detected bacterial pathogens, geospatial 
analyses of healthcare-seeking behavior and cases, socioeco-
nomic and WASH risk factors, cost of illness, and long-term 
socioeconomic impact to patients.
DISCUSSION
The SETA study protocol was aligned with the SEAP phase 
II [32, 33] and the STT project [31] under the recommenda-
tions of the Scientific Advisory Process for Optimal Research 
on Typhoid. Capacity building to support the existing public 
healthcare facilities selected as the SETA sentinel sites was 
Table 7. Formula for Incidence Estimations
Variable Definition
ni Number of cases (S. Typhi, iNTS, S. Paratyphi) during surveillance period in age group i
si Number of severe typhoid fever cases during surveillance period in age group i
1ni Population present in catchment area at the start of surveillance in age group i
2ni Estimated population present in catchment area at the end of surveillance in age group i
ri Recruitment proportion of eligible patients in SETA healthcare facilities in age group i
hi Proportion of population visiting SETA health care facilities (HCUS) in age group i
Adni Adjusted cases in age group i
Adsi Adjusted cases of severe typhoid in age group i 
PYOi Population in person years observation in catchment area in age group i
APYOi (Adjusted PYO) Adjusted population at risk contributing to PYO in age group i (accounting for new, lost to 
follow-up, deceased individuals during surveillance period)
Incidence of non-severe TF/PF/iNTS (TSAP-stylea incidence 
estimation using multipliers of healthcare utilisation and re-
cruitment proportion)
Incidence per 100,000 
= (new lab confirmed cases)/(population at risk) x 100,000 
HDSS site: 
Numerator: Adni 
Adni = ni x 1/ri 
Denominator: APYOi 
APYOi = PYOi x hi 
Adjusted incidence ratei in 100,000 PYO = (Adni/APYOi) x 100,000 
Non-HDSS site: 
Numerator: Adni 
Adni = ni x 1/ri 
Denominator: APYOi 
2ni = 1ni x (annual growth rate) x [(months of surveillance)/12] 
PYOi = [(1ni+2ni)/2] x [(months of surveillance)/12] 
APYOi = PYOi x hi 
Adjusted incidence ratei in 100,000 PYO = (Adni/APYOi) x 100,000
Incidence of severe TF Number of severe typhoid fever cases during surveillance period in age group i: si 
Numerator: Adsi 
Adsi = si x 1/ri 
Denominator: APYOi 
APYOi = PYOi x hi 
Incidence rate si in 100,000 
= (severe TF cases)/(population at risk) x 100,000 
Adjusted incidence rate si in 100,000 PYO 
= (Adsi/APYOi) x 100,000
Frequency proportion of severe TF Number of severe typhoid fever cases out of total laboratory confirmed typhoid fever cases 
in percentages
Abbreviations: APYO, adjusted person-years of observation; HCUS, healthcare utilization survey; iNTS, invasive nontyphoidal Salmonella; NTS, nontyphoidal Salmonella; PF, paratyphoid
fever; PYO, person-years of observation; SETA, Severe Typhoid Fever in Africa program; TF, typhoid fever; TSAP, Typhoid Fever Surveillance in Africa Program.
avon Kalckreuth, V, Konings F, Aaby P, et al. The Typhoid Fever Surveillance in Africa Program (TSAP): Clinical, Diagnostic, and Epidemiological Methodologies. Clin. Infect. Dis 2016; 62:S9-S16.
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essential for conducting a standardized surveillance in multiple 
sites in resource-limited settings. Active engagements of the 
healthcare professionals and field enumerators participating 
in the study were critical in ensuring a proper screening of 
eligible patients and reducing rates of missed screening or/
and dropouts from the surveillance and follow-up activities. 
Applying various adjustment factors in a selective healthcare 
facility–based surveillance is considered to be a relatively low-
cost hybrid surveillance method [30], whereby conducting a 
surveillance in all healthcare facilities in the study catchment 
area or/and an active community-based surveillance is not 
feasible.
Challenges were faced and addressed during the study period. 
These included the following: (1) introducing a complex research 
study with multiple study components, especially in tertiary 
hospitals, was challenging as the clinicians were occupied with 
their routine patient care; (2) contamination rates of blood cul-
ture varied per site; (3) volume of blood draw was challenging, 
particularly from children; (4) enrolling healthy controls in the 
neighborhood was also challenging and some loss to follow-up 
was inevitable over the course of 1 year; and (5) follow-up visit 
schedules were difficult to strictly adhere to, owing to various un-
foreseen and unexpected reasons such as the absence or refusal 
of the study participants. The SETA monitoring and evaluation 
plan and tool was developed and implemented throughout the 
study period (see Mogeni et al in this supplement) to ensure and 
improve the quality of surveillance across all sites.
The SETA program aimed to provide a comprehensive quan-
titative analysis of incidence, severity, complications, mor-
tality, host immunity, and acute and long-term carriage, cost 
of illness, and socioeconomic burden of disease associated 
with invasive salmonellosis in multiple countries across the 
sub-Saharan African region. Upon completion of the study, 
data cleaning and analysis will be performed, and the results 
will be disseminated at academic conferences and international 
peer-reviewed journals. Observational descriptions of the sur-
veillance study areas and populations including demographic 
and socioeconomic status, and WASH conditions and practices, 
will also provide a valuable dataset for the development of pre-
vention policies for TF/PF/iNTS disease, including vaccination 
strategies, in the respective African countries. SETA results will 
further serve as baseline data for any future vaccination studies 
in these study sites.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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